One strategy that has been tried to increase the cytotoxic activity of CD8 T cells and to overcome the immunosuppressiveness of the tumor microenvironment is the administration of immunotherapy in combination: checkpoint inhibitors with non-overlapping mechanisms of action such as an anti-PD-1 and an anti-CTLA-4 have been evaluated in several tumor types (4), which increased response rates but also the frequency and severity of immune related adverse events (5, 6). Here, CTLA4 is linked to neoplasm.